Phosphagenics appoints pharma veteran
By Dylan Bushell-Embling
Tuesday, 08 July, 2008
Tuesday, 08 July, 2008
Phosphagenics [ASX: POH] has appointed Michael Ashton to its board as a non-executive director.
Ashton will also act as a consultant on the Melbourne's company's commercialisation strategies.
Ashton has worked for over three decades in the international pharmaceutical industry, including having held senior management positions at Merck, Pfizer and Faulding.
Ashton also served as CEO for SkyePharma PLC.
Related News
Protein-based therapy helps the body remove harmful cells
Scientists have created a protein-based therapeutic tool that could change the way we treat...
Diabetes changes the structure of our hearts, study finds
Type 2 diabetes directly alters the heart's structure and energy systems, which explains why...
Beta blockers could halt triple negative breast cancer
Researchers have identified a molecular biomarker in triple negative breast cancer tumours which...
